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Introduction
Biliary tract cancers are invasive adenocarcinomas that arise 
from the epithelial lining of the gallbladder and intrahepatic 
and extra hepatic bile ducts. Although anatomically these 
malignancies are related and have similar metastatic 
patterns, each has a distinct clinical presentation, molecular 
pathology, and prognosis (1).
Gallbladder cancer is the most common malignancy of 
the biliary tract, representing 80-95% of biliary tract cancers 
worldwide (2,3). It ranks fifth among gastrointestinal cancers.
The global rates for gallbladder cancer shows differences, 
reaching epidemic levels for some regions and ethnicities. 
Gallbladder cancer has a particularly high incidence in 
Chile, Japan, and northern India (2).
The basis for this variance likely resides in differences in 
environmental exposure and intrinsic genetic predisposition 
to carcinogenesis. For gallbladder cancer, several conditions 
associated with chronic inflammation are considered 
risk factors, which include gallstone disease, porcelain 
gallbladder, gallbladder polyps, chronic Salmonella infection, 
congenital biliary cysts, and abnormal pancreaticobiliary 
duct junction (1,2).
The percentage of patients diagnosed to have gallbladder 
cancer after simple cholecystectomy for presumed 
gallbladder stone disease is 0.5-1.5% (4-6).
In most instances, gallbladder cancer develops over 5 to 
15 years, when metaplasia progresses to dysplasia, carcinoma 
in situ, and then, invasive cancer (1).
A satisfactory outcome depends on an early diagnosis and 
surgical resection. Despite this potential for cure, less than 
10% of patients have tumors that are resectable at the time 
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of surgery, while nearly 50% have lymph node metastasis (4). 
Even with surgery, most progress to metastatic disease, 
highlighting the importance of improving adjuvant 
therapies (5).
This tumour is traditionally regarded as a highly lethal 
disease with an overall 5-year survival of less than 5% (5). 
The overall mean survival rate for patients with gallbladder 
cancer is 6 months (6).
Risk factors
The identification of risk factors is critical, providing insight 
into the pathogenetic mechanism that drives geographic 
and ethnic variance, and yielding strategies for prevention 
and treatment.
Gallbladder cancer rates tend to increase with advancing 
age. The median age was 67 years in a Memorial Sloan-
Kettering report of 435 gallbladder cancer patients (5).
Gender differences demonstrate a marked predominance 
of women over men worldwide (7). Women are affected 
2-6 times more often than men (8).
There is a widely variable geographic pattern for 
gallbladder cancer, Asia is a high risk continent, while the 
United States and most western and Mediterranean European 
countries (e.g., UK, France, and Norway) represent low risk 
areas (5,6,9,10).
Ethnicity plays a role even in different geographic 
locations. The Korean people have the highest incidence 
rate (per 100,000) of gallbladder cancer in Asia. Korean 
males living in Los Angeles County, California also carry 
the highest US ethnic incidence rate (10).
Gallstones represent a most important association for 
this malignancy, being present in most (~85%) patients with 
gallbladder cancer. The incidence of gallbladder cancer in 
a population with gallstones varies from 0.3% to 3% (11).
The higher risk of gallbladder cancer development in larger 
stones possibly reflects the greater duration and intensity 
of mucosal irritation causing chronic inflamation (12,13). 
Prophylactic cholecystectomy would appear reasonable in 
these individuals (14).
Chronic inflammation causing deoxyribonucleic acid 
(DNA) damage, provoking repeated tissue proliferative 
attempts at restoration, releasing cytokines and growth 
factors, and thus, predisposing cells to oncogenic 
transformation (15). Chronic inflammation can also result 
in calcium being deposited in the gallbladder wall. When 
calcium deposits become extensive, the gallbladder acquires 
a bluish hue and becomes fragile, even brittle—hence the 
term “porcelain gallbladder” (16). The porcelain gallbladder 
is frequently (average 25%, range, 12-61%) associated with 
gallbladder cancer (17,18).
Chronic bacterial cholangitis poses a clear risk for biliary 
tract malignancy. The organisms that have been most 
implicated are Salmonella (e.g., S. typhi and S. paratyphi) and 
Helicobacter (e.g., H. bilis) spp (19,20). Bacterial colonization 
may induce hydrolysis of primary bile acids forming. 
Malignant transformation is further implicated via chronic 
inflammation itself and alterations of tumor suppressor 
genes [such as tumor protein 53 (p53)] or proto-oncogenes 
[such as mutations of Kirsten ras oncogene homolog (K-ras)] 
(15,21).
Primary sclerosing cholangitis (PSC) is a chronic 
fibroinflammatory syndrome linking chronic inflammation 
to carcinogenesis (22). Facilitating a metaplasia-dysplasia-
carcinoma sequence (23,24).
Various environmental exposures have been hypothesized 
to contribute to gallbladder cancer, such as: heavy metals, 
tobacco, radon (25-28).
Obese people have an increased risk of developing 
gallbladder cancer (29-31). The risk of developing gallbladder 
cancer in those with diabetes mellitus is increased (32).
Almost 5% of adults harbor gallbladder polyps (33,34). 
Most of them are pseudopolyps, without neoplastic 
potential (35). Features that predict malignancy are: large 
polyps (>10 mm), a solitary or sessile mass, associated 
gallstones, the patient’s age over 50 years old, and most 
importantly, rapid polyp growth (7,29).
Anomalous junction of the pancreaticobiliary duct is 
a congenital malformation in which the pancreatic duct 
drains into the biliary tract outside the papilae Vateri. Such 
a long common channel defeats the gatekeeper function 
of the sphincter of Oddi, potentially allowing pancreatic 
secretions to regurgitate into the bile ducts and gallbladder, 
thus leading to malignant changes in the mucosa (36).
Gallbladder cancer seems to result from a combination of 
genetic predisposition and exposure to environmental risk 
factors (37). One proposed carcinogenic pathways suggest 
that: gallstone mediated inflammation → p53 mutation (↓) 
→ K-ras mutation (↑) (21).
Diagnosis
Clinical presentation is similar to biliary colic or chronic 
cholecystitis. The most common symptoms are: persistent 
right upper quadrant pain, jaundice, nausea and weight loss. 
In some patients palpable mass is present (38,39).
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Imaging can detect malignancy. Transabdominal 
ultrasound is a useful initial modality for investigating 
patients with upper abdominal pain and jaundice (40).
Endoscopic ultrasound (EUS) is currently the definitive 
modality for staging gallbladder cancer. EUS also offers 
sampling via fine needle aspiration (41).
Computerized tomography (CT) helps identify any 
extension to lymph nodes, liver involvement, or distant 
metastases, performed preoperatively, determines gallbladder 
resectability with a high accuracy (up to 93%) (42) .
Standard magnetic resonance imaging (MRI) is generally 
less valuable. Magnetic resonance (MR) cholangiography 
and MR angiography quite accurately detects bile duct 
or vascular invasion, with sensitivity and specificity 
approaching 100%.
Positron emission computed tomography (PET) scans 
are useful in differentiating malignant from benign disease, 
in preoperative staging, and in detecting postoperative 
residual disease (43).
Staging system
Gallbladder cancer staging, based on the American Joint 
Committee on Cancer (AJCC) guidelines, focuses on tumor 
invasion and the extent of spread (44).
Adenocarcinoma is the most frequent histologic type, 
accounting for 98% of all gallbladder tumors (45). The 
other histopathologic variants include the papillary, 
mucinous, squamous, and adenosquamous subtypes. The 
disease stage determines the treatment options. The 
best outcomes are reserved for patients who qualify for 
cholecystectomy. In stage I disease, according to AJCC 
criteria, tumor invades the lamina propria or the muscle 
layer. Stage II is designated by the perforation of the 
serosa and/or involvement of adjacent organs or structures. 
T1 to T3 tumor invasion with any nodal involvement 
is automatically classified as stage II. Both stage I and 
II are potentially resectable with curative intent. Stage 
III generally indicates locally unresectable disease, as 
a consequence of vascular invasion or the involvement 
of  mult iple adjacent organs.  Stage IV represents 
nonresectability because of distant metastases (46).
Surgical management
Primary tumor invasion (T) is the most important factor 
in the AJCC staging criteria; it determines the surgical 
approach (44). The overall 5-year survival for patients with 
gallbladder cancer who underwent R0 curative resection 
was reported to range from 21% to 69%, and 0% for 
patients who did not get R0 resection. So the R0 curative 
resection is objective of surgical management for gallbader 
cancer (40).
Type of liver resection for carcinoma of the gallbladder 
varies from atipical resection of segments IVb at V to right 
hepatectomy.
By the Union for internatonal Cancer Control (UICC)/
AJCC are two types of regional lymphadenectomy for 
gallbladder cancer:
N1—lymphnodes of hepatoduodenal ligament (cystic 
duct, pericholedochal and hilar lymph nodes); 
N2—peripancreatic, periductal, periportal, common 
hepatic artery, coeliac and superior mesenteric artery lymph 
nodes.
Laparoscopic cholecystectomy is absolutely contraindicated 
when gallbladder cancer is known or suspected pre-operatively. 
Patients with a pre-operative suspicion of gallbladder cancer 
should undergo open exploration and cholecystectomy 
after proper pre-operative assessment, or immediately 
with suspicion made during laparoscopy. If the diagnosis is 
confirmed on frozen section radical surgical resection should 
be performed in the same session (5).
Incidental gallbladder cancers are detected histologically 
after the fact in 0.3-3% of laparoscopic cholecystectomies 
performed for cholelithiasis. For these patients a second 
radical resection is indicated after adequate diagnostic and 
treatment preparation, except for Tis and T1a disease.
Port-s i te  recurrences  can fo l low laparoscopic 
cholecystectomies in up to 17% of cases where unsuspected 
gallbladder cancer is discovered (47). Here, accidental bile 
spillage implants tumor cells at the trocar or incision site, 
leading to recurrence so the excision of the port sites are 
indicated during the radical reoperation.
Tis and T1a gallblader cancer (tumor is limited to 
mucosa) are usually diagnosed after cholecystectomy. There 
is consensus that simple cholecystectomy is an adequate 
treatment which offers a surgical cure with 100% 5-year 
survival (47).
In T1b gallbladder cancer (tumor invades the muscular 
layer) there is still controversy for the optimal management. 
Reported incidence of occult lymphatic metastasis is 15-
25% in this stage with 10% incidence of residual disease 
in liver bed (47,48). Given the frequency of positive lymph 
nodes and residual disease in this stage, recommended 
procedure is cholecystectomy with radical resection which 
encompasses 3 cm of liver parenchyma segment IVb and V, 
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plus adequate lymphadenectomy (48,49). The outcome after 
simple cholecystectomy in this stage is 75% 10-year survival 
vs. 100% for radical operation.
T2 lesions of gallbladder cancer invade perimuscular 
connective tissue with no extension beyond the serosa or 
into the liver. The reported 5-year survival for patients with 
this stage of disease treated with simple cholecystectomy 
where 10-61% and 54-100% after radical resection. 
Yamaguchi reported that over 40% of these patients had 
positive margins after simple cholecystectomy with rate of 
positive lymph nodes of 19-62%. So radical resection is the 
method of choice for these patients. This often requires a 
more formal resection of segments IVb and V (48-50).
In T3 disease, the tumor may extend to the serosa, liver, 
and/or adjacent organs/structures. Under these circumstances, 
resection becomes more radical, including an extended 
right hepatectomy with possible caudate lobectomy (47), 
regional lymphadenectomy, and extirpation of other 
affected structures (46). Some centers further advocate 
pancreaticoduodenectomy to improve outcomes (47). There 
is 45-70% incidence of lymph node dissemination with 36% 
of residual disease (51).
T4 disease is widely disseminated through vascular 
invasion and/or metastasis. Lesions here are commonly 
unresectable and it is impossible to achieve R0 resection in 
this stage. Consequently palliative therapy which includes 
adequate pain control, surgical or non-surgical biliary 
drainage is more appropriate in this stage.
The goal of surgical intervention is to obtain R0 
resection. Surgical resection for advanced gallbaldder cancer 
is recommended only if a potentially curative R0 resection 
is technically possible (46,47,52).
Adjuvant therapy
Patients with gallbladder cancer often present in advanced 
stage of disease. In these patients adjuvant therapy with 
palliative therapy is the only way to treat though there is 
still no effective adjuvant therapy for gallbladder cancer.
Three classes of chemotherapeutics may be used: 
gemcitabine, fluoropyrimidine, and platinum compounds. 
Monotherapy has limited effect (43). Combination 
chemotherapy using gemcitabine and cisplatin offers a 
significant survival advantage for patients with advanced 
disease (51).
Radiotherapy has proven to be marginally useful in the 
setting of advanced disease.
Therapeutic agents, targeting cellular and molecular 
pathways, can impede tumor growth. Targeted therapy 
against epidermal growth factor receptor (EGFR) has 
demonstrated an antiproliferative effect in vitro and provides 
some optimism for a changing treatment paradigm in the 
future (53).
Unfortunately, the data supporting the use of adjuvant or 
neoadjuvant chemoradiotherapy is largely based on Phase II 
trials, with no conclusive evidence favoring benefit (46).
Prognosis
The most important prognostic factors that can predict 
survival after resection are: T staging of the original lesion; 
extent of nodal involvement; metastasis; and jaundice (which 
can signify biliary invasion and possible obstruction) (46).
The advent of gallbladder cancer staging has witnessed 
an improvement in overall 5-year survival rates, what is 
the merit of radical and successful surgical curing and 
advances in diagnosis (2). Further improvement in the 
treatment of this disease is expected from the progress of 
chemotherapy (53).
The AJCC “Cancer Staging Manual” assessed 10,000 
patients diagnosed with gallbladder cancer from 1989 to 
1996. The 5-year survival rates start at 80% for stage 0, 
then progressively fall to 50% for stage I, 28% for stage II, 
8% for stage IIIa, 7% for stage IIIb, 4% for stage IVa, and 
finally, 2% for stage IVb (44).
Conclusions
Gallbladder cancer is the fifth most common cancer 
involving gastrointestinal tract, but it is the most common 
malignancy of the biliary tract with a highly variable 
prevalence in different parts of the world. Histopathological 
type is almost always adenocarcinoma.
This distinctive malignancy has disastrous outcomes with 
an overall 5-year survival of less than 5% and mean survival 
mere than 6 months.
Chronic inflammation caused with cholelithiasis is the 
most important risk factor.
Diagnosis may come at the time of cholecystectomy 
for gallstones, although preoperative imaging with 
transabdominal and EUS, multisliced computed tomography 
(MSCT) and MR is providing an important advance.
Surgery represents the only potential cure. Unfortunately, 
the usual late presentation means an advanced stage with 
potential nodal involvement and leads to recurrences despite 
attempted resection.
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Laparoscopic cholecystectomy is contraindicated when 
gallbladder cancer is suspected preoperatively. After 
incidental finding of gallbladder cancer on pathohistological 
review following cholecystectomy for cholelithiasis, a 
second radical resection is indicated except for T1a stage.
There is still no effective adjuvant therapy for gallbladder 
cancer so R0 surgical resection is the only treatment with 
potential cure. Aggressive surgical approach should be 
based on a balance between the risk of surgery (morbidity, 
mortality) and the outcome.
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